Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
a study on Solid Tumor Lung Cancer Non-Small Cell Lung Cancer Melanoma Skin Cancer/Melanoma Sarcoma Ewing Sarcoma Bone Cancer Osteosarcoma Leiomyosarcoma Synovial Sarcoma Liposarcoma Soft Tissue Sarcoma
Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Leiomyosarcoma, Synovial Sarcoma, Liposarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Refractory Sarcoma, late stage, stage 3, stage 4, cancer, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Peripheral, Immune Checkpoint Inhibitors, CAB-AXL-ADC, PD-1 inhibitor
Lead Scientist at University of California Health
- Brian Schulte, MD (ucsf)
Dr. Brian Schulte is a hematologist-oncologist who cares for patients with sarcomas, rare cancers that develop in connective tissues (such as bone, muscle or cartilage) and can affect people of all ages. Working as part of a multidisciplinary team, he strives to ensure patients receive the best possible comprehensive care.
- accepting new patients
- Start Date
- Completion Date
- BioAtla, Inc.
- Phase 1/2 research study
- Study Type
- Expecting 120 study participants
- Last Updated